Literature DB >> 22502989

On the safety and benefits of repeated intravenous injections of ketamine for depression.

Pierre Blier, Daniel Zigman, Jean Blier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22502989     DOI： 10.1016/j.biopsych.2012.02.039

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  19 in total

Review 1.  Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

Authors:  Chadi G Abdallah; Lynnette A Averill; John H Krystal
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

Review 2.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

Review 3.  Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?

Authors:  Gerard Sanacora; Alan F Schatzberg
Journal:  Neuropsychopharmacology       Date:  2014-09-26       Impact factor: 7.853

Review 4.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 5.  Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.

Authors:  Chadi G Abdallah; Gerard Sanacora; Ronald S Duman; John H Krystal
Journal:  Annu Rev Med       Date:  2014-10-17       Impact factor: 13.739

6.  Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.

Authors:  Ella J Daly; Madhukar H Trivedi; Adam Janik; Honglan Li; Yun Zhang; Xiang Li; Rosanne Lane; Pilar Lim; Anna R Duca; David Hough; Michael E Thase; John Zajecka; Andrew Winokur; Ilona Divacka; Andrea Fagiolini; Wieslaw J Cubala; István Bitter; Pierre Blier; Richard C Shelton; Patricio Molero; Husseini Manji; Wayne C Drevets; Jaskaran B Singh
Journal:  JAMA Psychiatry       Date:  2019-09-01       Impact factor: 21.596

7.  Development of the Ketamine Side Effect Tool (KSET).

Authors:  Brooke Short; Vanessa Dong; Verònica Gálvez; Vedran Vulovic; Donel Martin; Adam J Bayes; Carlos A Zarate; James W Murrough; Declan M McLoughlin; Patricio Riva-Posse; Robert Schoevers; Renerio Fraguas; Paul Glue; Johnson Fam; Rupert McShane; Colleen K Loo
Journal:  J Affect Disord       Date:  2020-01-25       Impact factor: 4.839

Review 8.  Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Erica M Richards; Carlos A Zarate
Journal:  J Neural Transm (Vienna)       Date:  2013-12-08       Impact factor: 3.575

Review 9.  KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.

Authors:  Chadi G Abdallah; Thomas G Adams; Benjamin Kelmendi; Irina Esterlis; Gerard Sanacora; John H Krystal
Journal:  Depress Anxiety       Date:  2016-04-06       Impact factor: 6.505

10.  Sex- and dose-dependent abuse liability of repeated subanesthetic ketamine in rats.

Authors:  Kristin J Schoepfer; Caroline E Strong; Samantha K Saland; Katherine N Wright; Mohamed Kabbaj
Journal:  Physiol Behav       Date:  2017-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.